Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13794
Country/Region: Ethiopia
Year: 2018
Main Partner: Oromia Health Bureau - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $6,799,920 Additional Pipeline Funding: $549,388

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $494,827
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $315,659
Care: Pediatric Care and Support (PDCS) $328,753
Laboratory Infrastructure (HLAB) $432,565
Strategic Information (HVSI) $225,612
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $762,168
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $3,638,188
Treatment: Pediatric Treatment (PDTX) $602,148
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 14
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 109
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 115
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 132
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 48
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 187
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 436
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 127
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 17
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 289
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 542
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 7
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 60
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 296
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 47
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 50
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 43
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 42
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 42
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 41
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 14
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 1,109
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1,120
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 1,683
GEND_GBV Number of people receiving post-GBV care 2019 2,824
HTS_SELF 2019 960
HTS_SELF 15-19, Female, Directly-Assisted 2019 60
HTS_SELF 15-19, Female, Unassisted 2019 3
HTS_SELF 15-19, Male, Directly-Assisted 2019 49
HTS_SELF 20-24, Female, Directly-Assisted 2019 91
HTS_SELF 20-24, Male, Directly-Assisted 2019 84
HTS_SELF 25-29, Female, Directly-Assisted 2019 94
HTS_SELF 25-29, Male, Directly-Assisted 2019 107
HTS_SELF 30-34, Female, Directly-Assisted 2019 78
HTS_SELF 30-34, Male, Directly-Assisted 2019 67
HTS_SELF 35-39, Female, Directly-Assisted 2019 77
HTS_SELF 35-39, Male, Directly-Assisted 2019 67
HTS_SELF 40-49, Female, Directly-Assisted 2019 59
HTS_SELF 40-49, Male, Directly-Assisted 2019 83
HTS_SELF 50+, Female, Directly-Assisted 2019 20
HTS_SELF 50+, Male, Directly-Assisted 2019 21
HTS_SELF Directly-Assisted 2019 957
HTS_SELF FSW, Directly-Assisted 2019 421
HTS_SELF Unassisted 2019 3
HTS_TST <5, Unknown Sex, Negative 2019 508
HTS_TST 15-19, Female, Negative 2019 28
HTS_TST 15-19, Male, Negative 2019 19
HTS_TST 20-24, Female, Negative 2019 128
HTS_TST 20-24, Male, Negative 2019 81
HTS_TST 25-29, Female, Negative 2019 2,761
HTS_TST 25-29, Female, Negative 2019 547
HTS_TST 25-29, Female, Negative 2019 188
HTS_TST 25-29, Female, Negative 2019 565
HTS_TST 25-29, Male, Negative 2019 1,473
HTS_TST 25-29, Male, Negative 2019 623
HTS_TST 25-29, Male, Negative 2019 152
HTS_TST 25-29, Male, Negative 2019 566
HTS_TST 30-34, Female, Negative 2019 197
HTS_TST 30-34, Female, Negative 2019 447
HTS_TST 30-34, Female, Negative 2019 138
HTS_TST 30-34, Female, Negative 2019 554
HTS_TST 30-34, Male, Negative 2019 744
HTS_TST 30-34, Male, Negative 2019 383
HTS_TST 30-34, Male, Negative 2019 169
HTS_TST 30-34, Male, Negative 2019 547
HTS_TST 35-39, Female, Negative 2019 1,111
HTS_TST 35-39, Female, Negative 2019 446
HTS_TST 35-39, Female, Negative 2019 139
HTS_TST 35-39, Female, Negative 2019 290
HTS_TST 35-39, Male, Negative 2019 921
HTS_TST 35-39, Male, Negative 2019 384
HTS_TST 35-39, Male, Negative 2019 168
HTS_TST 35-39, Male, Negative 2019 282
HTS_TST 40-49, Female, Negative 2019 740
HTS_TST 40-49, Female, Negative 2019 323
HTS_TST 40-49, Female, Negative 2019 165
HTS_TST 40-49, Female, Negative 2019 275
HTS_TST 40-49, Male, Negative 2019 922
HTS_TST 40-49, Male, Negative 2019 470
HTS_TST 40-49, Male, Negative 2019 198
HTS_TST 40-49, Male, Negative 2019 272
HTS_TST 50+, Female, Negative 2019 31
HTS_TST 50+, Male, Negative 2019 31
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 40,936
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 2,124
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 2,472
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 3,058
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 184
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 187
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 555
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 371
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 747
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 744
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 1,446
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 965
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 802
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 349
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 284
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 524
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 480
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 107
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 107
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 106
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 172
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 172
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 279
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 230
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 553
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 507
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 108
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 95
HTS_TST_POS <5, Unknown Sex, Positive 2019 13
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 200
HTS_TST_POS 25-29, Female, Positive 2019 7
HTS_TST_POS 25-29, Female, Positive 2019 9
HTS_TST_POS 25-29, Female, Positive 2019 65
HTS_TST_POS 25-29, Male, Positive 2019 109
HTS_TST_POS 25-29, Male, Positive 2019 5
HTS_TST_POS 25-29, Male, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 56
HTS_TST_POS 30-34, Female, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 56
HTS_TST_POS 30-34, Male, Positive 2019 54
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 6
HTS_TST_POS 30-34, Male, Positive 2019 48
HTS_TST_POS 35-39, Female, Positive 2019 81
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 5
HTS_TST_POS 35-39, Female, Positive 2019 20
HTS_TST_POS 35-39, Male, Positive 2019 64
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 15
HTS_TST_POS 40-49, Female, Positive 2019 54
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 15
HTS_TST_POS 40-49, Male, Positive 2019 63
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS 40-49, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 52
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 66
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 74
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 47
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 46
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 2
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 6,668
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 6,668
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,387
PMTCT_ART New on ART 2019 595
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,982
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 1,737
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 168
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 438
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 40
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 2,175
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 208
PMTCT_EID Sum of Infant Age disaggregates 2019 2,175
PMTCT_EID Sum of Infant Age disaggregates 2019 208
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 18
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 402
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 45
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 419
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 881
TB_PREV By Age/Sex (Numerator): <15, Female 2019 523
TB_PREV By Age/Sex (Numerator): <15, Female 2019 968
TB_PREV By Age/Sex (Numerator): <15, Male 2019 989
TB_PREV By Age/Sex (Numerator): <15, Male 2019 1,112
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 4,230
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 8,582
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 4,682
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 9,107
TB_PREV IPT, Life-long ART, Already, Positive 2019 8,649
TB_PREV IPT, Life-long ART, Already, Positive 2019 16,236
TB_PREV IPT, Life-long ART, New, Positive 2019 1,778
TB_PREV IPT, Life-long ART, New, Positive 2019 3,328
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 10,425
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 19,573
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 10,704
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 20,971
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 538
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,054
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 1,015
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 1,152
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 4,360
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 8,894
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 4,831
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 9,034
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 8,883
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 17,387
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1,821
TB_PREV_den IPT, Life-long ART, New, Positive 2019 3,568
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 5
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 245
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 2,415
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 38
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 5
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 288
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 53
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 3,168
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 101
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. 2019 5,183
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 265
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 5,213
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 11
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 246
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 105
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 2,432
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 11
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 288
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 137
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 3,189
TX_CURR 25-29, Female, Positive 2019 3,668
TX_CURR 25-29, Female, Positive 2019 79
TX_CURR 25-29, Male, Positive 2019 1,612
TX_CURR 25-29, Male, Positive 2019 33
TX_CURR 30-34, Female, Positive 2019 10,600
TX_CURR 30-34, Female, Positive 2019 228
TX_CURR 30-34, Male, Positive 2019 3,028
TX_CURR 30-34, Male, Positive 2019 74
TX_CURR 35-39, Female, Positive 2019 9,729
TX_CURR 35-39, Female, Positive 2019 208
TX_CURR 35-39, Male, Positive 2019 3,579
TX_CURR 35-39, Male, Positive 2019 76
TX_CURR 40-49, Female, Positive 2019 22,562
TX_CURR 40-49, Female, Positive 2019 485
TX_CURR 40-49, Male, Positive 2019 16,079
TX_CURR 40-49, Male, Positive 2019 345
TX_CURR Age/Sex: <1 2019 134
TX_CURR Age/Sex: <1-9 2019 3,772
TX_CURR Age/Sex: 1-9 2019 37
TX_CURR Age/Sex: 10-14 Female 2019 2,415
TX_CURR Age/Sex: 10-14 Female 2019 26
TX_CURR Age/Sex: 10-14 Male 2019 2,326
TX_CURR Age/Sex: 10-14 Male 2019 42
TX_CURR Age/Sex: 15-19 Female 2019 4,018
TX_CURR Age/Sex: 15-19 Female 2019 86
TX_CURR Age/Sex: 15-19 Male 2019 3,239
TX_CURR Age/Sex: 15-19 Male 2019 68
TX_CURR Age/Sex: 20-24 Female 2019 4,915
TX_CURR Age/Sex: 20-24 Female 2019 104
TX_CURR Age/Sex: 20-24 Male 2019 3,315
TX_CURR Age/Sex: 20-24 Male 2019 71
TX_CURR Age/Sex: 50+ Female 2019 15,164
TX_CURR Age/Sex: 50+ Female 2019 327
TX_CURR Age/Sex: 50+ Male 2019 9,026
TX_CURR Age/Sex: 50+ Male 2019 195
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 122,629
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 2,544
TX_CURR Sum of age/sex disaggregates 2019 7,257
TX_CURR Sum of Age/Sex disaggregations 2019 154
TX_NEW 25-29, Female, Positive 2019 126
TX_NEW 25-29, Female, Positive 2019 4
TX_NEW 25-29, Male, Positive 2019 62
TX_NEW 25-29, Male, Positive 2019 2
TX_NEW 30-34, Female, Positive 2019 365
TX_NEW 30-34, Female, Positive 2019 12
TX_NEW 30-34, Male, Positive 2019 132
TX_NEW 30-34, Male, Positive 2019 4
TX_NEW 35-39, Female, Positive 2019 343
TX_NEW 35-39, Female, Positive 2019 11
TX_NEW 35-39, Male, Positive 2019 156
TX_NEW 35-39, Male, Positive 2019 4
TX_NEW 40-49, Female, Positive 2019 792
TX_NEW 40-49, Female, Positive 2019 26
TX_NEW 40-49, Male, Positive 2019 699
TX_NEW 40-49, Male, Positive 2019 20
TX_NEW Breastfeeding status 2019 1
TX_NEW By Age/Sex: <1 2019 25
TX_NEW By Age/Sex: <1 2019 6
TX_NEW By Age/Sex: 1-9 2019 159
TX_NEW By Age/Sex: 1-9 2019 17
TX_NEW By Age/Sex: 10-14 Female 2019 335
TX_NEW By Age/Sex: 10-14 Female 2019 25
TX_NEW By Age/Sex: 10-14 Male 2019 140
TX_NEW By Age/Sex: 10-14 Male 2019 16
TX_NEW By Age/Sex: 15-19 Female 2019 51
TX_NEW By Age/Sex: 15-19 Female 2019 4
TX_NEW By Age/Sex: 15-19 Male 2019 8
TX_NEW By Age/Sex: 15-19 Male 2019 2
TX_NEW By Age/Sex: 20-24 Female 2019 11
TX_NEW By Age/Sex: 20-24 Female 2019 2
TX_NEW By Age/Sex: 20-24 Male 2019 52
TX_NEW By Age/Sex: 20-24 Male 2019 2
TX_NEW By Age/Sex: 50+ Female 2019 306
TX_NEW By Age/Sex: 50+ Female 2019 15
TX_NEW By Age/Sex: 50+ Male 2019 201
TX_NEW By Age/Sex: 50+ Male 2019 10
TX_NEW FSW 2019 22
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 4,036
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 100
TX_NEW Pregnancy status 2019 353
TX_NEW Pregnancy status 2019 5
TX_NEW Sum of Age/Sex disaggregates 2019 1,104
TX_NEW Sum of Age/Sex disaggregates 2019 76
TX_PVLS <15, Undocumented Test Indication, Female 2019 1
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 106,283
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,128
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 531
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 2,337
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 528
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 51,309
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 9,012
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 34,344
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 6,062
TX_PVLS_den Denominator: Indication: Routine 2019 90,213
TX_PVLS_den Denominator: Indication: Targeted 2019 12,611
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 442
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 456
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 10,180
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 5,499
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 16,506
TX_RET Numerator by Status: Breastfeeding 2019 32
TX_RET Numerator by Status: Pregnant 2019 30
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 20,839
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 563
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 589
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 12,773
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 6,912
TX_RET_den Denominator by Status: Breastfeeding 2019 25
TX_RET_den Denominator by Status: Pregnant 2019 50
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 102,342
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 1,310
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 27
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 38
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 647
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 596
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 3,076
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 3,655
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 47,581
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 48,025
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 6,567
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 6
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 1,651
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 5,168
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 78,798
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 8,261
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 4,632
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 1,029
Cross Cutting Budget Categories and Known Amounts Total: $275,000
Gender: Gender Based Violence (GBV) $60,000
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation
Water $55,000
Adolescent Girls and Young Women (AGYW) $60,000
Human Resources for Health $100,000